ArticleFrontiers in immunology2025

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study.

Baoyue Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.